README.md

metadata

title: BioIntel
emoji: 🧬
colorFrom: blue
colorTo: green
sdk: gradio
sdk_version: 6.30.0
app_file: app.py
pinned: false
license: mit
short_description: Biotech catalysts from SEC filings and trials

BioIntel

Biotech catalyst intelligence built entirely from public sources.

Tab	What it shows
Catalyst feed	SEC 8-K filings matching 12 clinical/regulatory signal types — what already happened
Readout calendar	Industry trials with a primary completion date ahead — dated catalysts that have not happened yet
Demand mix	Modality mix of the upcoming pipeline, the closest public read on future wet-lab and manufacturing need

Sources

• SEC EDGAR full-text search (efts.sec.gov) — no key, 10 req/s ceiling, descriptive User-Agent required
• ClinicalTrials.gov API v2 — no key

Data is refreshed by a scheduled job and published as parquet to a Hugging Face Dataset repo, which this Space reads at startup.

Method notes

Catalyst phrases were chosen by measurement rather than assumption. Over a sample window, "met its primary endpoint" appeared in 54 filings while "met the primary endpoint" appeared in 19, and "topline data" outranked "topline results" — so each signal searches a group of variants. EDGAR accepts uppercase OR between quoted phrases; a | silently returns zero.

Both APIs truncate silently: one EDGAR call returns at most 100 hits regardless of the reported total, and filtering trials client-side after a truncated fetch drops most of the result set. Both are paged and filtered server-side here.

Limitations

Signals co-occur — one filing can match both endpoint met and endpoint missed, which is a real reporting pattern, not a bug. Trial completion dates are plans and slip. Modality is inferred and reports unknown rather than guessing. CRO lab occupancy, private lease terms and options flow are not obtainable from public data.

An information tool built on public filings. Not investment advice.